Ekso Bionics (EKSO) 10-Q 9 May 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 01, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Registrant Name	EKSO BIONICS HOLDINGS, INC.
Entity Central Index Key	1,549,084
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	EKSO
Entity Common Stock, Shares Outstanding		25,634,568

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 9,426	$ 16,846
Accounts receivable, net	1,282	1,780
Inventories, net	1,819	1,556
Prepaid expenses and other current assets	689	502
Deferred cost of revenue, current	46	0
Total current assets	13,262	20,684
Property and equipment, net	2,458	2,435
Intangible assets, net	894	1,026
Goodwill	189	189
Other assets	92	91
Total assets	16,895	24,425
Current liabilities:
Note payable, current	389	0
Accounts payable	2,867	1,879
Accrued liabilities	2,747	3,556
Deferred revenues, current	975	825
Capital lease obligation, current	43	54
Total current liabilities	7,021	6,314
Deferred revenue	776	805
Note payable	6,445	6,789
Warrant liability	3,615	3,546
Contingent consideration liability	217	217
Contingent success fee liability	117	116
Other non-current liabilities	87	107
Total liabilities	18,278	17,894
Commitments and contingencies (Note 14)
Stockholders' equity (deficit):
Common stock, $0.001 par value; 71,429 shares authorized; 21,902 and 21,894 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	22	22
Additional paid-in capital	121,880	121,291
Accumulated other comprehensive income	49	79
Accumulated deficit	(123,334)	(114,861)
Total stockholders' equity (deficit)	(1,383)	6,531
Total liabilities and stockholders' equity (deficit)	$ 16,895	$ 24,425

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets [Parenthetical] - $ / shares shares in Thousands	Mar. 31, 2017	Dec. 31, 2016
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	71,429	71,429
Common Stock, Shares, Issued	21,902	21,894
Common Stock, Shares, Outstanding	21,902	21,894

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Device and related	$ 1,408	$ 8,057
Engineering services	28	429
Total revenue	1,436	8,486
Cost of revenue:
Device and related	1,077	6,669
Engineering services	7	319
Total cost of revenue	1,084	6,988
Gross profit	352	1,498
Operating expenses:
Sales and marketing	3,067	2,503
Research and development	2,873	2,149
General and administrative	2,553	3,488
Total operating expenses	8,493	8,140
Loss from operations	(8,141)	(6,642)
Other income (expense), net:
Gain (loss) on warrant liability	(69)	2,985
Interest and other, net	(92)	6
Total other income (expense), net	(161)	2,991
Net loss	(8,302)	(3,651)
Less: Preferred deemed dividend	0	(3,124)
Net loss applicable to common shareholders	(8,302)	(6,775)
Foreign currency translation loss	(30)	0
Comprehensive loss applicable to common shareholders	$ (8,332)	$ (6,775)
Basic and diluted net loss per share applicable to common shareholders (in dollars per share)	$ (0.38)	$ (0.44)
Weighted average number of shares of common stock, basic (in shares)	21,899	15,388
Weighted average number of shares of common stock, diluted (in shares)	21,920	15,388

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities:
Net loss	$ (8,302)	$ (3,651)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	475	440
Amortization of deferred rent	(9)	(9)
Stock-based compensation expense	394	1,574
(Gain) loss on change in fair value of warrant liability	69	(2,985)
Accretion of end of term payment of note payable	24	0
Changes in operating assets and liabilities:
Accounts receivable	498	(314)
Inventories	(470)	(1,475)
Prepaid expense and other assets	(188)	(298)
Deferred costs of revenue	(46)	4,335
Accounts payable	988	924
Accrued liabilities	(808)	1,255
Deferred revenues	121	(6,585)
Net cash used in operating activities	(7,254)	(6,789)
Investing activities:
Acquisition of property and equipment	(138)	(285)
Net cash used in investing activities	(138)	(285)
Financing activities:
Principal payments on note payable	(22)	(19)
Fees paid related to 2015 issuance of convertible preferred stock	0	(173)
Proceeds from exercise of stock options	24	28
Net cash (used in) provided by financing activities	2	(164)
Effect of exchange rate changes on cash	(30)	0
Net decrease increase in cash	(7,420)	(7,238)
Cash at beginning of period	16,846	19,552
Cash at end of period	$ 9,426	$ 12,314

Organization

Organization	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Description of Business The Company designs, develops, and sells exoskeletons that augment human strength, endurance, and mobility. The Company’s exoskeletons have applications in health care, industrial, military, and consumer markets. All common stock share and per share amounts have been adjusted to reflect the one-for-seven reverse stock split completed on May 4, 2016. See Note 11, Capitalization and Equity Structure – Reverse Stock Split Liquidity Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of this technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. The Company has also recognized significant non-cash losses associated with the revaluation of certain securities, which have also contributed significantly to its accumulated deficit. As of March 31, 2017, the Company had an accumulated deficit of $ 123,334 Cash on hand at March 31, 2017 was $ 9,426 16,846 7,254 6,789 Long-Term Debt 6,678 2,748 3,732 1,866 10.9 Subsequent Events Based upon the Company’s current cash resources, cash raised in April 2017 from the sale of common stock, the recent rate of using cash for operations and investment, and assuming modest increases in current revenue offset by incremental increases in expenses related to increased sales and marketing and research and development, and a potential increase in rental activity from its medical device business, the Company believes it has sufficient resources to meet its financial obligations into the first quarter of 2018. The Company will require significant additional financing. The Company is actively pursuing opportunities to obtain additional financing in the future through public or private equity and/or debt financings, corporate collaborations, or warrant solicitations. The Company’s actual capital requirements may vary significantly and will depend on many factors. For example, the Company plans to continue to increase its investments (i) in its clinical, sales and marketing initiatives to accelerate adoption of the Ekso robotic exoskeleton in the rehabilitation market, (ii) in its research, development and commercialization activities with respect to an Ekso robotic exoskeleton for home use, and/or (iii) in the development and commercialization of able-bodied exoskeletons for industrial use. Consequently, the Company will require significant additional financing in the future, which the Company intends to raise through corporate collaborations, public or private equity offerings, debt financings, or warrant solicitations. Sales of additional equity securities by us could result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional financing is not obtained, the Company may be required to reduce its discretionary overhead costs substantially, including research and development, general and administrative, and sales and marketing expenses or otherwise curtail operations.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies and Estimates	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Estimates	2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for the presentation of interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2016, has been derived from the audited consolidated financial statements at that date but does not include all disclosures required for the annual financial statements and should be read in conjunction with our audited consolidated financial statements and notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2016. Unless otherwise indicated, all dollar and share amounts (excluding per share amounts) included in these notes to the condensed consolidated financial statements are in thousands. In management’s opinion, the condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary for a fair statement of its financial position as of March 31, 2017, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year. The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation. Certain reclassifications have been made to conform to the current period’s presentation. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates. The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with Accounting Standards Codification 205-40. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The ability to meet our obligations as they come due and the attainment of sustainable profitability and positive cash flow from operations is dependent on certain future events. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for the look-forward period one year from the issuance of these financial statements, even after considering approximately $ 10.9 Subsequent Events Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable. Accounts receivable are derived from the sale of products shipped to and services performed for customers. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and records an allowance for credit losses, as needed. The Company has not experienced any material losses related to accounts receivable as of March 31, 2017 and December 31, 2016. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable. As of March 31, 2017, we had three customers with an accounts receivable balance totaling 10 11 11 10 18 16 11 In the three months ended March 31, 2017, we had one customer with billed revenue of 10 26 27 20 11 10 The Company builds medical device robotic exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor and overhead in connection with the manufacture and assembly of these units. When the Company brought its first version medical device to market in 2012, the Company could not be certain as to the costs it would incur to support, maintain, service, and upgrade these early stage devices. Primarily for this reason, prior to January 1, 2016, the sale of a device, associated software, initial training, and extended support and maintenance were deemed as a single unit of accounting due to the uncertainty of the Company’s follow-up maintenance and upgrade expenses, which were forecast to extend over three years. Accordingly, the revenue from the sales of the device and associated cost of revenue were deferred at the time of shipment. Upon completion of training, the amount of the arrangements were recognized as revenue and cost of revenue over a three year period on a straight line basis, while all service expenses, whether or not covered by the Company’s original warranty, extended warranty contracts, or neither, were recognized as incurred. Effective January 1, 2016, the Company determined it had established (i) separate individual pricing for training, extended warranty coverage, and out-of-contract service or repairs, (ii) sufficient historical evidence of customer buying patterns for extended warranty and maintenance coverage, and (iii) a basis for estimating and recording warranty and service costs to allow the Company to separate its multiple element arrangements into two distinct units of accounting: (1) the device, associated software, original manufacturer warranty and training if required, and (2) extended support and maintenance. As a result, in the first quarter of 2016, the Company began to recognize revenue related to its sales transactions on a multiple element approach in which revenue is recognized upon the delivery of the separate elements to the customer. Revenue relating to the undelivered elements is deferred using the relative selling price method, which allocates revenue to each element using the estimated selling prices for the deliverables when vendor-specific objective evidence or third-party evidence is not available. For sales on or after January 1, 2016, revenue and associated cost of revenue of medical devices is recognized when delivered, or training has been completed, if required. Revenue for extended maintenance and support agreements is recognized on a straight line basis over the contractual term of the agreement, which typically ranges from one to four years. As a result of this change, the Company recognized medical device revenue previously deferred at December 31, 2015 of $ 6,517 4,159 2,358 0.13 212 911 In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09 Compensation – Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting 171 January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Income (Loss)	3. Accumulated Other Comprehensive Income Foreign Currency Translation Balance at December 31, 2016 $ 79 Other comprehensive loss before reclassification (30) Amounts reclassified from accumulated other comprehensive loss - Net current period other comprehensive loss (30) Balance at March 31, 2017 $ 49

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following: • Level 1 • Level 2 • Level 3 The Company’s fair value hierarchies for its financial assets and liabilities which require fair value measurement are as follows: Quoted Prices in Significant Active Markets Other Significant For Identical Observable For Identical Inputs Inputs Total (Level 1) (Level 2) (Level 3) March 31, 2017 Liabilities Warrant liability $ 3,615 $ - $ - $ 3,615 Contingent consideration liability $ 217 $ - $ - $ 217 Contingent success fee liability $ 117 $ - $ - $ 117 December 31, 2016 Liabilities Warrant liability $ 3,546 $ - $ - $ 3,546 Contingent consideration liability $ 217 $ - $ - $ 217 Contingent success fee liability $ 116 $ - $ - $ 116 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the three month period ended March 31, 2017, which were measured at fair value on a recurring basis: Contingent Contingent Warrant Consideration Success Fee Liability Liability Liability Balance at December 31, 2016 $ 3,546 $ 217 $ 116 Loss on increase in fair value of warrants issued in conjunction with 2015 financing 69 - - Loss on increase in fair value of obligation - - 1 $ 3,615 $ 217 $ 117 Refer to Note 11 Capitalization and Equity Structure – Warrants

Inventories, net

Inventories, net	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventories, net	5. Inventories, net March 31, December 31, 2017 2016 Raw materials $ 1,156 $ 1,193 Work in process 395 198 Finished goods 370 267 1,921 1,658 Less: inventory reserve (102) (102) Inventories, net $ 1,819 $ 1,556

Deferred Revenues and Cost of R

Deferred Revenues and Cost of Revenues	3 Months Ended
	Mar. 31, 2017
Deferred Revenue Disclosure [Abstract]
Deferred Revenues	6. Deferred Revenues and Cost of Revenues In connection with our medical device sales and engineering services, the Company often receives cash payments before the earnings process is complete. In these instances, the Company records the payments as customer deposits until a device is shipped to the customer, or as customer advances in the case of engineering services until the earnings process is achieved. In both cases, the cash received is recorded as a component of deferred revenue. Deferred revenues and deferred cost of revenues consist of the following: March 31, 2017 December 31, 2016 Customer deposits and advances $ 74 $ 47 Deferred rental income 93 60 Deferred extended maintenance and support 1,584 1,523 Total deferred revenues 1,751 1,630 Less current portion (975) (825) Deferred revenues, non-current $ 776 $ 805 Deferred medical device unit costs $ 46 $ - Less current portion (46) - Deferred cost of revenue, non-current $ - $ -

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	7. Intangible Assets Cost Accumulated Amortization Net Developed technology $ 1,160 $ (516) $ 644 Customer relationships 70 (31) 39 Customer trade name 380 (169) 211 $ 1,610 $ (716) $ 894 Estimated future amortization for the remainder of 2017 is $ 404 490

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Liabilities	8. Accrued Liabilities March 31 December 31, 2017 2016 Salaries, benefits and related expenses $ 1,581 $ 2,349 Device maintenance 404 483 Device warranty 157 203 Professional fees 56 56 Equipois earn-out 366 355 Other 183 110 Total $ 2,747 $ 3,556 A reconciliation of the changes in the current portion of maintenance and warranty liabilities for the period ended March 31, 2017 is as follows: 2017 Maintenance Warranty Total Balance at December 31, 2016 $ 483 $ 204 $ 687 Incurred costs (79) (47) (126) Balance at March 31, 2017 $ 404 $ 157 $ 561

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-Term Debt	9. Long-Term Debt In December 2016, the Company entered into a loan agreement and received $ 7,000 bears interest on the outstanding daily balance at a floating per annum rate equal to the 30 day U.S. LIBOR rate plus 5.41% . The 3,000 The loan agreement created a first priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself. The Company is required to pay accrued interest on the current loan on the first day of each month through and including January 1, 2018. Commencing on February 1, 2018, the Company is required make equal monthly payments of principal, together with accrued and unpaid interest. The principal balance of the current loan amortizes ratably over 36 months and matures on January 1, 2021 245 24 In December 2016, and pursuant to the loan agreement, the Company entered into a success fee agreement with the lender under which the Company agreed to pay the lender a $ 250 8.00 The fair value of the contingent success fee is re-measured each reporting period with any adjustments in fair value being recognized in the condensed consolidated statement of operations and comprehensive loss. The success fee is classified as a liability on the consolidated balance sheets. At March 31, 2017, the carrying value of the contingent success fee liability was $ 117 The loan agreement includes a liquidity covenant requiring that the Company maintain unrestricted cash and cash equivalents in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least three months of “Monthly Cash Burn,” which is the Company’s average monthly net income (loss) for the trailing six-month period plus certain expenses and plus the average monthly principal due and payable on interest-bearing liabilities in the immediately succeeding three-month period. Such amount was determined to be $6,678 as of March 31, 2017, the most current determination, with the amount subject to change on a month-to-month basis. At March 31, 2017, with cash on hand of $ 9,426 The final payment fee, debt issuance costs, and the initial fair value of the success fee combined with the stated interest result in an effective annual interest rate of 8.78 for three month period ended March 31, 2017. The final payment fee, the initial fair value of the success fee and debt issuance costs will be accreted and amortized, respectively, to interest expense using the effective interest method over the life of the loan. The following table presents scheduled principal payments of our long-term debt, including the accreted portion of the final payment fee due in 2021, as of March 31, 2017: Period Amount 2017 $ - 2018 2,139 2019 2,333 2020 2,333 2021 219 Total principal payments 7,024 Less issuance costs and debt discount 190 Long-term debt, net $ 6,834 Current portion 389 Long-term portion 6,635 Total principal payments $ 7,024

Lease and Note Obligations

Lease and Note Obligations	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Lease and Note Obligations	10. Lease and Note Obligations The Company has an operating lease agreement for its headquarters and manufacturing facility in Richmond, California that expires in May 2022. In addition, the Company leases nominal office space in Germany. The Company has a note for $ 200 7 In August 2015, the Company entered into a long-term capital lease obligation for equipment. The aggregate principal of the lease is $ 166 4.7 3 July 1, 2020 March 31, 2017 Period Operating Lease Note Payable Capital Lease Total Minimum Payments 2017 - remainder $ 342 $ 8 $ 30 $ 38 2018 479 - 37 37 2019 491 - 37 37 2020 500 - 22 22 2021 429 - - - Thereafter 181 - - - Total minimum payments $ 2,422 8 126 134 Less interest - (9) (9) Present value minimum payments 8 117 125 less current portion (8) (35) (43) Long-term portion $ - $ 82 $ 82 Rent expense under the Company’s operating leases was $ 101 96

Capitalization and Equity Struc

Capitalization and Equity Structure	3 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Capitalization and Equity Structure	11. Capitalization and Equity Structure Reverse Stock Split: After the close of the stock market on May 4, 2016, the Company effected a 1-for-7 reverse Summary: The Company’s authorized capital stock at March 31, 2017 consisted of 71,429 10,000 21,902 Warrants: Warrant shares outstanding as of December 31, 2016 and March 31, 2017 is as follows: Source Exercise Term At December 31, Issued Exercised Expired At March 31, Warrants issued in conjunction with 2015 Series A Preferred financing $ 3.74 5 1,634 1,634 2014 PPO and Merger Placement agent warrants $ 7.00 5 426 426 Bridge warrants $ 7.00 3 371 (371) - PPO warrants $ 14.00 5 1,078 1,078 Pre 2014 warrants $ 9.66 9-10 88 88 3,597 - - (371) 3,226 In January 2014, the Company issued various warrants with a three year life to investors who participated in the Company’s November 2013 private placement of senior subordinated secured convertible notes, of which warrant representing 371 The December 2015 warrants contain a put-option provision. Under this provision, while the warrants are outstanding, if the Company enters into a Fundamental Transaction, defined as a merger, consolidation or similar transaction, the Company or any successor entity will, at the option of each warrant holder, exercisable at any time within 30 days after the consummation of the Fundamental Transaction, purchase the warrant from the holder exercising such option by paying to the holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s warrant on the date of the consummation of the Fundamental Transaction. As a result of this put-option provision, these warrants are classified as a liability and are marked to market at each reporting date. The warrant liability is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the valuation hierarchy. The following assumptions were used in the Black Scholes Option Pricing Model to measure the fair value of the warrants as of March 31, 2017: Current share price $ 4.10 Conversion price $ 3.74 Risk-free interest rate 1.66 % Term (years) 3.73 Volatility of stock 70 % At December 31, 2016, the warrants were valued at $ 3,546 69

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments	12. Stock-based Compensation The Company’s Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”) allows for the issuance of an aggregate of 3,714 952 Weighted- Average Remaining Stock Weighted- Contractual Aggregat Awards Exercise Price (Years) Value Balance as of December 31, 2016 2,477 $ 6.50 Options granted 56 $ 3.47 Options exercised (8) $ 3.05 Options forfeited (40) $ 8.97 Options cancelled (19) $ 7.63 Balance as of March 31, 2017 2,466 $ 6.39 7.31 $ 801 Vested and expected to vest at March 31, 2017 2,466 7.31 $ 801 Exercisable as of March 31, 2017 1,352 6.06 $ 723 As of March 31, 2017, total unrecognized compensation cost related to unvested stock options was $ 4,162 2.5 Three months ended March 31, 2017 2016 Dividend yield — — Risk-free interest rate 2.05% - 2.40% 1.24% - 1.78% Expected term (in years) 6-10 5-10 Volatility 80% - 82% 77% Three months ended March 31, 2017 2016 Sales and marketing $ 20 $ 232 Research and development 101 231 General and administrative 273 1,111 $ 394 $ 1,574 In connection with the resignation of the Company’s then Chief Executive Officer in February 2016, the Company accelerated the vesting of options that would have vested in the subsequent twelve months and extended the exercise period of the resulting options from three months to six years. In addition, the Company extended the exercise period for an employee that was terminated in March 2016 from three months to one year. These modifications resulted in incremental stock-based compensation expense of $ 59 774 In June 2015 an employee of the Company received a performance based option grant representing a total of 99,999 124 condensed consolidated statement of operations and comprehensive loss under sales and marketing for the three month period ended March 31, 2017

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	13 . Income Taxes There were no material changes to the unrecognized tax benefits in the three months ended March 31, 2017, and the Company does not expect significant changes to unrecognized tax benefits through the end of the fiscal year. Because of the Company’s history of tax losses, all years remain open to tax examination.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Contingencies In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company’s condensed consolidated financial statements. Material Contracts The Company enters into various license, research collaboration and development agreements which provide for payments to the Company for government grants, fees, cost reimbursements typically with a markup, technology transfer and license fees, and royalty payments on sales. The Company has two license agreements to maintain exclusive rights to patents. The Company is also required to pay 1 21 1 50 In connection with acquisition of Equipois, the Company assumed the rights and obligations of Equipois under a license agreement with the developer of certain intellectual property related to mechanical balance and support arm technologies, which grants the Company an exclusive license with respect to the technology and patent rights for certain fields of use. Pursuant to the terms of the license agreement, the Company will be required to pay the developer a single-digit royalty on net receipts, subject to a $ 50 U.S. Food and Drug Administration Clearance On April 4, 2016, the Company received clearance from the U.S. Food and Drug Administration (“FDA”) to market its Ekso GT robotic exoskeleton for use in the treatment of individuals with hemiplegia due to stroke, individuals with spinal cord injuries at levels T4 to L5, and individuals with spinal cord injuries at levels of T3 to C7 (ASIA D), in accordance with the device’s labeling. On July 19, 2016, the Company received clearance from the FDA to expand/clarify the indications and labeling to expressly include individuals with hemiplegia due to stroke who have upper extremity function of at least 4/5 in only one arm. The Company’s prior cleared indications for use statement required that individuals with hemiplegia due to stroke have upper extremity function of at least 4/5 in both arms.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	15. Net Loss Per Share Three months ended March 31, 2017 2016 Numerator: Net loss applicable to common shareholders, basic and diluted $ (8,302) $ (6,775) Denominator: Weighted-average number of shares, basic 21,899 15,338 Effect of dilutive warrants 21 - Weighted-average number of shares, diluted 21,920 15,338 Net loss per share, basic and diluted $ (0.38) $ (0.44) March 31, 2017 2016 Options to purchase common stock 2,466 1,979 Warrants for common stock 1,592 4,085 Common stock issuable upon conversion of preferred shares - 1,309 Total common stock equivalents 4,058 7,373

Segment Disclosures

Segment Disclosures	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segment Disclosures	16. Segment Disclosures The Company has three reportable segments: Medical Devices, Industrial Sales, and Engineering Services. The Medical Devices segment designs and engineers technology for, and commercializes, manufactures, and sells exoskeletons for applications in the medical markets. The Industrial Sales segment designs, engineers, commercializes, and sells exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. Engineering Services generates revenue principally from collaborative research and development service arrangements, technology license agreements, and government grants where the Company uses its robotics domain knowledge in bionic exoskeletons to bid on and procure contracts and grants from entities such as the National Science Foundation and the Defense Advanced Research Projects Agency. The Company evaluates performance and allocates resources based on segment gross profit margin. The reportable segments are each managed separately because they serve distinct markets, and one segment provides a service and the others manufacture and distribute unique products. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated. Device and related Total Medical Industrial Total Engineering All Three months ended March 31, 2017 Revenue $ 870 $ 538 $ 1,408 $ 28 $ 1,436 Cost of revenue 721 356 1,077 7 1,084 Gross profit $ 149 $ 182 $ 331 $ 21 $ 352 Three months ended March 31, 2016 Revenue $ 7,922 $ 135 $ 8,057 $ 429 $ 8,486 Cost of revenue 6,524 145 6,669 319 6,988 Gross profit $ 1,398 $ (10) $ 1,388 $ 110 $ 1,498 Three months ended March 31, 2017 2016 United States $ 931 $ 4,521 All Other 505 3,965 $ 1,436 $ 8,486

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events In April 2017, the Company sold in a registered direct offering an aggregate of 3,732 0.001 1,866 4.10 3.14 11.7 10.9 On May 2, 2017, as consideration for 2016 supply and sales efforts provided by Equipois, LLC, the Company issued a total of 89,286

Basis of Presentation and Sum23

Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for the presentation of interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2016, has been derived from the audited consolidated financial statements at that date but does not include all disclosures required for the annual financial statements and should be read in conjunction with our audited consolidated financial statements and notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2016. Unless otherwise indicated, all dollar and share amounts (excluding per share amounts) included in these notes to the condensed consolidated financial statements are in thousands. In management’s opinion, the condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary for a fair statement of its financial position as of March 31, 2017, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year. The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation. Certain reclassifications have been made to conform to the current period’s presentation.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates.
Going Concern	Going Concern The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with Accounting Standards Codification 205-40. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The ability to meet our obligations as they come due and the attainment of sustainable profitability and positive cash flow from operations is dependent on certain future events. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for the look-forward period one year from the issuance of these financial statements, even after considering approximately $ 10.9 Subsequent Events
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable. Accounts receivable are derived from the sale of products shipped to and services performed for customers. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and records an allowance for credit losses, as needed. The Company has not experienced any material losses related to accounts receivable as of March 31, 2017 and December 31, 2016. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable. As of March 31, 2017, we had three customers with an accounts receivable balance totaling 10 11 11 10 18 16 11 In the three months ended March 31, 2017, we had one customer with billed revenue of 10 26 27 20 11 10
Revenue and Cost of Revenue Recognition	Medical Device Revenue and Cost of Revenue Recognition The Company builds medical device robotic exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor and overhead in connection with the manufacture and assembly of these units. When the Company brought its first version medical device to market in 2012, the Company could not be certain as to the costs it would incur to support, maintain, service, and upgrade these early stage devices. Primarily for this reason, prior to January 1, 2016, the sale of a device, associated software, initial training, and extended support and maintenance were deemed as a single unit of accounting due to the uncertainty of the Company’s follow-up maintenance and upgrade expenses, which were forecast to extend over three years. Accordingly, the revenue from the sales of the device and associated cost of revenue were deferred at the time of shipment. Upon completion of training, the amount of the arrangements were recognized as revenue and cost of revenue over a three year period on a straight line basis, while all service expenses, whether or not covered by the Company’s original warranty, extended warranty contracts, or neither, were recognized as incurred. Effective January 1, 2016, the Company determined it had established (i) separate individual pricing for training, extended warranty coverage, and out-of-contract service or repairs, (ii) sufficient historical evidence of customer buying patterns for extended warranty and maintenance coverage, and (iii) a basis for estimating and recording warranty and service costs to allow the Company to separate its multiple element arrangements into two distinct units of accounting: (1) the device, associated software, original manufacturer warranty and training if required, and (2) extended support and maintenance. As a result, in the first quarter of 2016, the Company began to recognize revenue related to its sales transactions on a multiple element approach in which revenue is recognized upon the delivery of the separate elements to the customer. Revenue relating to the undelivered elements is deferred using the relative selling price method, which allocates revenue to each element using the estimated selling prices for the deliverables when vendor-specific objective evidence or third-party evidence is not available. For sales on or after January 1, 2016, revenue and associated cost of revenue of medical devices is recognized when delivered, or training has been completed, if required. Revenue for extended maintenance and support agreements is recognized on a straight line basis over the contractual term of the agreement, which typically ranges from one to four years. As a result of this change, the Company recognized medical device revenue previously deferred at December 31, 2015 of $ 6,517 4,159 2,358 0.13 212 911
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09 Compensation – Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting 171 January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment.

Accumulated Other Comprehensi24

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure Text Block [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The change in accumulated other comprehensive income presented on the condensed consolidated balance sheets and the impact of significant amounts reclassified from accumulated other comprehensive income (loss) on information presented in the condensed consolidated statements of operations and comprehensive loss for the three month period ending March 31, 2017, are reflected in the table below net of tax: Foreign Currency Translation Balance at December 31, 2016 $ 79 Other comprehensive loss before reclassification (30) Amounts reclassified from accumulated other comprehensive loss - Net current period other comprehensive loss (30) Balance at March 31, 2017 $ 49

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The Company’s fair value hierarchies for its financial assets and liabilities which require fair value measurement are as follows: Quoted Prices in Significant Active Markets Other Significant For Identical Observable For Identical Inputs Inputs Total (Level 1) (Level 2) (Level 3) March 31, 2017 Liabilities Warrant liability $ 3,615 $ - $ - $ 3,615 Contingent consideration liability $ 217 $ - $ - $ 217 Contingent success fee liability $ 117 $ - $ - $ 117 December 31, 2016 Liabilities Warrant liability $ 3,546 $ - $ - $ 3,546 Contingent consideration liability $ 217 $ - $ - $ 217 Contingent success fee liability $ 116 $ - $ - $ 116
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the three month period ended March 31, 2017, which were measured at fair value on a recurring basis: Contingent Contingent Warrant Consideration Success Fee Liability Liability Liability Balance at December 31, 2016 $ 3,546 $ 217 $ 116 Loss on increase in fair value of warrants issued in conjunction with 2015 financing 69 - - Loss on increase in fair value of obligation - - 1 $ 3,615 $ 217 $ 117

Inventories, net (Tables)

Inventories, net (Tables)	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories consist of the following: March 31, December 31, 2017 2016 Raw materials $ 1,156 $ 1,193 Work in process 395 198 Finished goods 370 267 1,921 1,658 Less: inventory reserve (102) (102) Inventories, net $ 1,819 $ 1,556

Deferred Revenues and Cost of27

Deferred Revenues and Cost of Revenues (Tables)	3 Months Ended
	Mar. 31, 2017
Deferred Revenue Disclosure [Abstract]
Schedule of Customer Deposits, Advances, Deferred Revenues, and Deferred Unit Costs	Deferred revenues and deferred cost of revenues consist of the following: March 31, 2017 December 31, 2016 Customer deposits and advances $ 74 $ 47 Deferred rental income 93 60 Deferred extended maintenance and support 1,584 1,523 Total deferred revenues 1,751 1,630 Less current portion (975) (825) Deferred revenues, non-current $ 776 $ 805 Deferred medical device unit costs $ 46 $ - Less current portion (46) - Deferred cost of revenue, non-current $ - $ -

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	The following table reflects the amortization of the purchased intangible assets as of March 31, 2017: Cost Accumulated Amortization Net Developed technology $ 1,160 $ (516) $ 644 Customer relationships 70 (31) 39 Customer trade name 380 (169) 211 $ 1,610 $ (716) $ 894

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following: March 31 December 31, 2017 2016 Salaries, benefits and related expenses $ 1,581 $ 2,349 Device maintenance 404 483 Device warranty 157 203 Professional fees 56 56 Equipois earn-out 366 355 Other 183 110 Total $ 2,747 $ 3,556
Product Maintenance And Warrantyy [Table Text Block]	A reconciliation of the changes in the current portion of maintenance and warranty liabilities for the period ended March 31, 2017 is as follows: 2017 Maintenance Warranty Total Balance at December 31, 2016 $ 483 $ 204 $ 687 Incurred costs (79) (47) (126) Balance at March 31, 2017 $ 404 $ 157 $ 561

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt	The following table presents scheduled principal payments of our long-term debt, including the accreted portion of the final payment fee due in 2021, as of March 31, 2017: Period Amount 2017 $ - 2018 2,139 2019 2,333 2020 2,333 2021 219 Total principal payments 7,024 Less issuance costs and debt discount 190 Long-term debt, net $ 6,834 Current portion 389 Long-term portion 6,635 Total principal payments $ 7,024

Lease and Note Obligations (Tab

Lease and Note Obligations (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Schedule of Maturities of Future Obligations	The Company estimates future minimum payments as of March 31, 2017 Period Operating Lease Note Payable Capital Lease Total Minimum Payments 2017 - remainder $ 342 $ 8 $ 30 $ 38 2018 479 - 37 37 2019 491 - 37 37 2020 500 - 22 22 2021 429 - - - Thereafter 181 - - - Total minimum payments $ 2,422 8 126 134 Less interest - (9) (9) Present value minimum payments 8 117 125 less current portion (8) (35) (43) Long-term portion $ - $ 82 $ 82

Capitalization and Equity Str32

Capitalization and Equity Structure (Tables)	3 Months Ended
	Mar. 31, 2017
Schedule of Warrant share activity	Warrant shares outstanding as of December 31, 2016 and March 31, 2017 is as follows: Source Exercise Term At December 31, Issued Exercised Expired At March 31, Warrants issued in conjunction with 2015 Series A Preferred financing $ 3.74 5 1,634 1,634 2014 PPO and Merger Placement agent warrants $ 7.00 5 426 426 Bridge warrants $ 7.00 3 371 (371) - PPO warrants $ 14.00 5 1,078 1,078 Pre 2014 warrants $ 9.66 9-10 88 88 3,597 - - (371) 3,226
Warrant [Member]
Schedule of assumption used in valuation	The following assumptions were used in the Black Scholes Option Pricing Model to measure the fair value of the warrants as of March 31, 2017: Current share price $ 4.10 Conversion price $ 3.74 Risk-free interest rate 1.66 % Term (years) 3.73 Volatility of stock 70 %

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes information about the Company’s stock options outstanding at March 31, 2017, and activity during the three month period then ended: Weighted- Average Remaining Stock Weighted- Contractual Aggregat Awards Exercise Price (Years) Value Balance as of December 31, 2016 2,477 $ 6.50 Options granted 56 $ 3.47 Options exercised (8) $ 3.05 Options forfeited (40) $ 8.97 Options cancelled (19) $ 7.63 Balance as of March 31, 2017 2,466 $ 6.39 7.31 $ 801 Vested and expected to vest at March 31, 2017 2,466 7.31 $ 801 Exercisable as of March 31, 2017 1,352 6.06 $ 723
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The per-share fair value of each stock option was determined on the date of grant using the Black-Scholes option pricing model using the following assumptions: Three months ended March 31, 2017 2016 Dividend yield — — Risk-free interest rate 2.05% - 2.40% 1.24% - 1.78% Expected term (in years) 6-10 5-10 Volatility 80% - 82% 77%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	Total stock-based compensation expense related to options granted to employees and non-employees was included in the condensed consolidated statements of operations and comprehensive loss as follows: Three months ended March 31, 2017 2016 Sales and marketing $ 20 $ 232 Research and development 101 231 General and administrative 273 1,111 $ 394 $ 1,574

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of basic and diluted net loss per share: Three months ended March 31, 2017 2016 Numerator: Net loss applicable to common shareholders, basic and diluted $ (8,302) $ (6,775) Denominator: Weighted-average number of shares, basic 21,899 15,338 Effect of dilutive warrants 21 - Weighted-average number of shares, diluted 21,920 15,338 Net loss per share, basic and diluted $ (0.38) $ (0.44)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	March 31, 2017 2016 Options to purchase common stock 2,466 1,979 Warrants for common stock 1,592 4,085 Common stock issuable upon conversion of preferred shares - 1,309 Total common stock equivalents 4,058 7,373

Segment Disclosures (Tables)

Segment Disclosures (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	Segment reporting information is as follows: Device and related Total Medical Industrial Total Engineering All Three months ended March 31, 2017 Revenue $ 870 $ 538 $ 1,408 $ 28 $ 1,436 Cost of revenue 721 356 1,077 7 1,084 Gross profit $ 149 $ 182 $ 331 $ 21 $ 352 Three months ended March 31, 2016 Revenue $ 7,922 $ 135 $ 8,057 $ 429 $ 8,486 Cost of revenue 6,524 145 6,669 319 6,988 Gross profit $ 1,398 $ (10) $ 1,388 $ 110 $ 1,498
Schedule of Geographic Information	Geographic information for revenue based on location of customer is as follows: Three months ended March 31, 2017 2016 United States $ 931 $ 4,521 All Other 505 3,965 $ 1,436 $ 8,486

Organization (Details Textual)

Organization (Details Textual) - USD ($) $ in Thousands	May 02, 2017	Apr. 30, 2017	Mar. 31, 2017	Mar. 31, 2016	Jan. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Organization [Line Items]
Retained Earnings (Accumulated Deficit), Total			$ (123,334)			$ (114,861)
Cash and Cash Equivalents, at Carrying Value, Total			9,426	$ 12,314		$ 16,846	$ 19,552
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total			(7,254)	$ (6,789)
Restricted Cash and Cash Equivalents			6,678		$ 6,206
Unrestricted Cash And Cash Equivalents			$ 2,748
Subsequent Event [Member]
Organization [Line Items]
Stock Issued During Period, Shares, New Issues	89,286	3,732
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,866
Proceeds from Issuance of Common Stock		$ 10,900

Basis of Presentation and Sum37

Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 30, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Jan. 31, 2017
Subsequent Event [Member]
Significant Accounting Policies [Line Items]
Proceeds from Issuance of Common Stock	$ 10,900
Accounting Standards Update 2016-09 [Member]
Significant Accounting Policies [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets						$ 171
Medical Device [Member]
Significant Accounting Policies [Line Items]
Deferred Revenue, Revenue Recognized					$ 6,517
Cost of Revenue					$ 4,159
Product Liability Accrual, Component Amount			$ 212
Customer Advances and Deposits, Current			911
Reduction In Net Loss Attributable To Common Stock Holders			$ 2,358
Reduction Percentage In Net Loss Attributable To Common Stock Holders			$ 0.13
Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		10.00%
Customer One [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		11.00%		18.00%
Customer One [Member] | Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		26.00%	27.00%
Customer Two [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		11.00%		16.00%
Customer Two [Member] | Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage			20.00%
Customer Three [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		10.00%		11.00%
Customer Three [Member] | Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage			11.00%
Customer Four [Member] | Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage			10.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		10.00%

Accumulated Other Comprehensi38

Accumulated Other Comprehensive Income (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Balance at December 31, 2016	$ 79
Other comprehensive loss before reclassification	(30)
Amounts reclassified from accumulated other comprehensive loss	0
Net current period other comprehensive income	(30)
Balance at March 31, 2017	$ 49

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Liabilities:
Warrant liability	$ 3,615	$ 3,546
Contingent Success Fee Liability		117
Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	3,615	3,546
Contingent consideration liability	217	217
Contingent Success Fee Liability	117	116
Quoted Prices in Active Markets for Identical Items Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	0	0
Contingent consideration liability	0	0
Contingent Success Fee Liability	0	0
Significant Other Observable Inputs Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	0	0
Contingent consideration liability	0	0
Contingent Success Fee Liability	0	0
Significant Unobservable Inputs Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	3,615	3,546
Contingent consideration liability	217	217
Contingent Success Fee Liability	$ 117	$ 116

Fair Value Measurements (Deta40

Fair Value Measurements (Details 1) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Derivative Financial Instruments, Liabilities [Member]
Balance	$ 3,546
Loss on increase in fair value of warrants issued in conjunction with 2015 financing	69
Loss on increase in fair value of obligation	0
Balance	3,615
Contingent Consideration [Member]
Balance	217
Loss on increase in fair value of warrants issued in conjunction with 2015 financing	0
Loss on increase in fair value of obligation	0
Balance	217
Contingent Success Fee [Member]
Balance	116
Loss on increase in fair value of warrants issued in conjunction with 2015 financing	0
Loss on increase in fair value of obligation	1
Balance	$ 117

Inventories, net (Details)

Inventories, net (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Raw materials	$ 1,156	$ 1,193
Work in process	395	198
Finished goods	370	267
Inventory, Gross	1,921	1,658
Less: inventory reserve	(102)	(102)
Inventories, net	$ 1,819	$ 1,556

Deferred Revenues and Cost of42

Deferred Revenues and Cost of Revenues (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Deferred Revenue Arrangement [Line Items]
Deferred rental income	$ 93	$ 60
Deferred Revenue	1,751	1,630
Less current portion	(975)	(825)
Deferred revenues, non-current	776	805
Deferred medical device unit costs	46	0
Less current portion	46	0
Deferred cost of revenue, non-current	0	0
Customer deposits and advances [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue	74	47
Deferred extended maintenance and support [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue	$ 1,584	$ 1,523

Intangible Assets (Details Text

Intangible Assets (Details Textual) $ in Thousands	May 01, 2017USD ($)
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 404
Finite-Lived Intangible Assets, Amortization Expense, Year Two	$ 490

Intangible Assets (Details)

Intangible Assets (Details) $ in Thousands	Mar. 31, 2017USD ($)
Indefinite-lived Intangible Assets [Line Items]
Cost	$ 1,610
Accumulated Amortization	(716)
Net	894
Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Cost	1,160
Accumulated Amortization	(516)
Net	644
Customer Relationships [Member]
Indefinite-lived Intangible Assets [Line Items]
Cost	70
Accumulated Amortization	(31)
Net	39
Customer Lists [Member]
Indefinite-lived Intangible Assets [Line Items]
Cost	380
Accumulated Amortization	(169)
Net	$ 211

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accrued Liabilities [Line Items]
Salaries, benefits and related expenses	$ 1,581	$ 2,349
Device maintenance	404	483
Device warranty	157	203
Professional fees	56	56
Equipois earn-out	366	355
Other	183	110
Total	$ 2,747	$ 3,556

Accrued Liabilities (Details 1)

Accrued Liabilities (Details 1) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Accrued Liabilities [Line Items]
Beginning Balance	$ 687
Incurred costs	(126)
Closing Balance	561
Maintenance [Member]
Accrued Liabilities [Line Items]
Beginning Balance	483
Incurred costs	(79)
Closing Balance	404
Warranty [Member]
Accrued Liabilities [Line Items]
Beginning Balance	204
Incurred costs	(47)
Closing Balance	$ 157

Long-Term Debt (Details)

Long-Term Debt (Details) $ in Thousands	Mar. 31, 2017USD ($)
2,017	$ 0
2,018	2,139
2,019	2,333
2,020	2,333
2,021	219
Total principal payments	7,024
Less issuance costs and debt discount	190
Long-term debt, net	6,834
Current portion	389
Long-term portion	6,635
Total principal payments	$ 7,024

Long-Term Debt (Details Textual

Long-Term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Dec. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jan. 31, 2017	Dec. 31, 2015
Success Fee Expenses	$ 250
Share Price	$ 8
Contingent Success Fee Liability	$ 117
Debt Instrument, Interest Rate, Stated Percentage		8.78%
Restricted Cash and Cash Equivalents		$ 6,678		$ 6,206
Cash and Cash Equivalents, at Carrying Value, Total	16,846	9,426	$ 12,314		$ 19,552
Debt Instrument, Unused Borrowing Capacity, Amount		3,000
Accretion Expense		24	$ 0
Long-term Debt		$ 6,834
Loan Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 7,000
Debt Instrument, Description of Variable Rate Basis	30 day U.S. LIBOR rate plus 5.41%
Debt Instrument, Maturity Date		Jan. 1, 2021
Long-term Debt		$ 245

Lease and Note Obligations (Det

Lease and Note Obligations (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
2017 - remainder	$ 38
2,018	37
2,019	37
2,020	22
2,021	0
Thereafter	0
Total minimum payments	134
Less interest	(9)
Present value minimum payments	125
less current portion	(43)	$ (54)
Long-term portion	82
Lease hold Improvement Note [Member]
Debt Instrument [Line Items]
2017 - remainder	8
2,018	0
2,019	0
2,020	0
2,021	0
Thereafter	0
Total minimum payments	8
Less interest	0
Present value minimum payments	8
less current portion	(8)
Long-term portion	0
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
2017 - remainder	30
2,018	37
2,019	37
2,020	22
2,021	0
Thereafter	0
Total minimum payments	126
Less interest	(9)
Present value minimum payments	117
less current portion	(35)
Long-term portion	82
Operating Lease [Member]
Debt Instrument [Line Items]
2017 - remainder	342
2,018	479
2,019	491
2,020	500
2,021	429
Thereafter	181
Total minimum payments	$ 2,422

Lease and Note Obligations (D50

Lease and Note Obligations (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 7,024
Debt Instrument, Interest Rate, Stated Percentage	8.78%
Operating Leases, Rent Expense, Net, Total	$ 101	$ 96
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 166
Debt Instrument, Interest Rate, Stated Percentage	4.70%
Debt Instrument, Maturity Date	Jul. 1, 2020
Debt Instrument Minimum Monthly Payments	$ 3
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 200
Debt Instrument, Interest Rate, Stated Percentage	7.00%
Debt Instrument, Maturity Date		Mar. 31, 2017

Capitalization and Equity Str51

Capitalization and Equity Structure (Details) - $ / shares shares in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Schedule of Capitalization, Equity [Line Items]
Merger/PPO Warrant Shares Outstanding	3,226	3,597
Merger/PPO Warrant Shares Issued	0
Merger/PPO Warrant Shares Exercised	0
Merger/PPO Warrant Shares Expired	(371)
2015 Series A Preferred Warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 3.74
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	1,634	1,634
Placement agent warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 7
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	426	426
Bridge warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 7
Warrant term	3 years
Merger/PPO Warrant Shares Outstanding	0	371
Merger/PPO Warrant Shares Expired	(371)
PPO warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 14
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	1,078	1,078
Pre 2014 Warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 9.66
Merger/PPO Warrant Shares Outstanding	88	88
Pre 2014 Warrants [Member] | Minimum [Member]
Schedule of Capitalization, Equity [Line Items]
Warrant term	9 years
Pre 2014 Warrants [Member] | Maximum [Member]
Schedule of Capitalization, Equity [Line Items]
Warrant term	10 years

Capitalization and Equity Str52

Capitalization and Equity Structure (Details 1) - $ / shares	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Schedule of Capitalization, Equity [Line Items]
Current share price		$ 8
Black-Scholes Option Pricing Model [Member] | Warrant [Member]
Schedule of Capitalization, Equity [Line Items]
Current share price	$ 4.10
Conversion price	$ 3.74
Risk-free interest rate	1.66%
Term (years)	3 years 8 months 23 days
Volatility of stock	70.00%

Capitalization and Equity Str53

Capitalization and Equity Structure (Details Textual) - USD ($) shares in Thousands, $ in Thousands	Jan. 02, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Class of Stock [Line Items]
Common Stock, Shares Authorized		71,429		71,429
Preferred Stock, Shares Authorized		10,000
Common Stock, Shares, Issued		21,902		21,894
Fair Value Adjustment of Warrants			$ 69
Warrants Not Settleable in Cash, Fair Value Disclosure				$ 3,546
Stockholders' Equity, Reverse Stock Split		1-for-7 reverse
Warrants to Purchase Common Stock, Expiration During the Period	371

Stock-based Compensation (Detai

Stock-based Compensation (Details) - 2014 Plan [Member] $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Options Outstanding
Options Outstanding, Beginning Balance | shares	2,477
Options Outstanding, Options granted | shares	56
Options Outstanding, Options exercised | shares	(8)
Options Outstanding, Options forfeited | shares	(40)
Options Outstanding, Options cancelled | shares	(19)
Options Outstanding, Ending Balance | shares	2,466
Options Outstanding, Vested and expected to vest | shares	2,466
Options Outstanding, Exercisable | shares	1,352
Weighted-Average Exercise Price, Beginning Balance | $ / shares	$ 6.5
Weighted-Average Exercise Price, Options granted | $ / shares	3.47
Weighted-Average Exercise Price, Options exercised | $ / shares	3.05
Weighted-Average Exercise Price, Options forfeited | $ / shares	8.97
Weighted-Average Exercise Price, Options cancelled | $ / shares	7.63
Weighted-Average Exercise Price, Ending Balance | $ / shares	6.39
Weighted-Average Exercise Price, Vested and expected to vest | $ / shares	0
Weighted-Average Exercise Price, Exercisable | $ / shares	$ 0
Weighted-Average Remaining Contractual Life (Years), Ending Balance	7 years 3 months 22 days
Weighted-Average Remaining Contractual Life (Years), Vested and expected to vest	7 years 3 months 22 days
Weighted-Average Remaining Contractual Life (Years), Exercisable	6 years 22 days
Aggregate Intrinsic Value, Ending Balance | $	$ 801
Aggregate Intrinsic Value, Vested and expected to vest | $	801
Aggregate Intrinsic Value, Exercisable | $	$ 723

Stock-based Compensation (Det55

Stock-based Compensation (Details 1)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Risk-free interest rate, minimum	2.05%	1.24%
Risk-free interest rate, maximum	2.40%	1.78%
Volatility		77.00%
Volatility, minimum	80.00%
Volatility, maximum	82.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years	5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	10 years	10 years

Stock-based Compensation (Det56

Stock-based Compensation (Details 2) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 394	$ 1,574
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	20	232
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	101	231
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 273	$ 1,111

Stock-based Compensation (Det57

Stock-based Compensation (Details Textual) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended	3 Months Ended
	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total		$ 394	$ 1,574
Performance Based Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	99,999
Share-based Compensation, Total		124
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total			59
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total			$ 774
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 4,162
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 6 months
Equity Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		3,714
Common Stock, Capital Shares Reserved for Future Issuance		952

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Future minimum annual royalties:
Payments Due By Period, Less than one year	$ 50
Royalty Agreement Terms [Member]
Future minimum annual royalties:
Payments Due By Period, Less than one year	$ 50
Royalty Agreement Terms [Member] | Net sales [Member]
Future minimum annual royalties:
Royalty Percentage	1.00%
Royalty Agreement Terms [Member] | License fees [Member]
Future minimum annual royalties:
Royalty Percentage	21.00%
Royalty Agreement Terms [Member] | Sub-licensee net sales [Member]
Future minimum annual royalties:
Royalty Percentage	1.00%

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net loss applicable to common shareholders, basic and diluted	$ (8,302)	$ (6,775)
Denominator:
Weighted-average number of shares, basic	21,899	15,388
Effect of dilutive warrants	21	0
Weighted-average number of shares, diluted	21,920	15,388
Net loss per share applicable to common stockholders
Net loss per share, basic and diluted	$ (0.38)	$ (0.44)

Net Loss Per Share (Details 1)

Net Loss Per Share (Details 1) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	4,058	7,373
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	2,466	1,979
Warrants for common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,592	4,085
Common stock issuable upon conversion of preferred shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	0	1,309

Segment Disclosures (Details)

Segment Disclosures (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Revenue	$ 1,436	$ 8,486
Cost of revenue	1,084	6,988
Gross profit	352	1,498
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	1,408	8,057
Cost of revenue	1,077	6,669
Gross profit	331	1,388
Medical [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	870	7,922
Cost of revenue	721	6,524
Gross profit	149	1,398
Industrial [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	538	135
Cost of revenue	356	145
Gross profit	182	(10)
Engineering [Member]
Segment Reporting Information [Line Items]
Revenue	28	429
Cost of revenue	7	319
Gross profit	$ 21	$ 110

Segment Disclosures (Details 1)

Segment Disclosures (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Revenue	$ 1,436	$ 8,486
United States [Member]
Segment Reporting Information [Line Items]
Revenue	931	4,521
All Other [Member]
Segment Reporting Information [Line Items]
Revenue	$ 505	$ 3,965

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions	May 02, 2017	Apr. 30, 2017	Mar. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Common Stock, Par or Stated Value Per Share			$ 0.001	$ 0.001
Class of Warrant or Right, Expiration Term			5 years
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	89,286	3,732
Common Stock, Par or Stated Value Per Share		$ 0.001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,866
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.10
Shares Issued, Price Per Share		$ 3.14
Stock Issued During Period, Value, New Issues		$ 11.7
Proceeds from Issuance of Common Stock		$ 10.9